Tibet Rhodiola Pharmaceutical Holding (600211) Fundamentals 2026 — P/E 12.9x, Revenue Analysis | SniperIQ
Tibet Rhodiola Pharmaceutical Holding (600211) is a CN-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of ¥12.4B, trading at ¥38.62 on the SHH. This SniperIQ fundamentals page covers Tibet Rhodiola Pharmaceutical Holding's valuation (P/E 12.9x, P/B 3.2x), profitability (net margin 32.3%), revenue (¥3.0B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Tibet Rhodiola Pharmaceutical Holding's market cap?
Tibet Rhodiola Pharmaceutical Holding (600211) has a market capitalization of approximately ¥12.4B, trading at ¥38.62 on the SHH. Market cap moves with the live share price.
What is Tibet Rhodiola Pharmaceutical Holding's P/E ratio?
Tibet Rhodiola Pharmaceutical Holding's trailing twelve-month P/E ratio is 12.9x, with a price-to-book (P/B) of 3.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Tibet Rhodiola Pharmaceutical Holding?
Tibet Rhodiola Pharmaceutical Holding runs a net profit margin of 32.3%, a gross margin of 93.4%, and an operating margin of 31.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Tibet Rhodiola Pharmaceutical Holding generate?
Tibet Rhodiola Pharmaceutical Holding reported revenue of ¥3.0B for fiscal year 2025, with net income of ¥938M and earnings per share (EPS) of 2.91. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Tibet Rhodiola Pharmaceutical Holding pay a dividend?
Tibet Rhodiola Pharmaceutical Holding offers a trailing dividend yield of about 4.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Tibet Rhodiola Pharmaceutical Holding financially healthy?
Tibet Rhodiola Pharmaceutical Holding carries a debt-to-equity ratio of 0.27x and a current ratio of 2.88x, with a market beta of 0.25. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Tibet Rhodiola Pharmaceutical Holding a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Tibet Rhodiola Pharmaceutical Holding (600211) the key facts are: market cap ¥12.4B, P/E 12.9x, revenue ¥3.0B, 52-week range 34.8-57.98. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Tibet Rhodiola Pharmaceutical Holding's full fundamentals live
Get Tibet Rhodiola Pharmaceutical Holding's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.